Document resource
Background and Importance The combination of encorafenib and binimetinib is a standard option for BRAF-mutated metastatic melanoma. However, its clinical management is complex due to the risk of class-related toxicities. Pharmaceutical care may play a key role in early identification of adverse effects, supporting treatment adjustments and improving patient safety.Aim and Objectives To describe pharmaceutical interventions made during treatment with encorafenib/binimetinib and analyse their association with the occurrence of toxicities, treatment duration and therapeutic outcomes.Material and Methods Multicentre, retrospective study that included all patients with unresectable or metastatic melanoma treated with encorafenib/binimetinib since their introduction in hospital guidelines. Data collected: sex, age, treatment duration and outcomes (partial/complete response, stable disease, or tumour progression), reported toxicities (hepatic, muscular, renal, cutaneous) and pharmaceutical interventions. Data were collected from medical electronic record system and analysed using R commander.Results A total of 38 patients were included (84% male) with a median age of 63 years (IQR 47–73). BRAF V600E mutation was present in 89.4% of cases. Prior treatment had been received by 64.8% of patients: nivolumab in 92.1% and dabrafenib/trametinib in 7.9%. The most frequent metastatic sites were lung (36.8%), lymph nodes (31.5%), peritoneum (21.1%), and brain (21.1%). Median treatment duration with encorafenib/binimetinib was 22.5 months (IQR 12–37). Clinical outcomes included complete response in 42.1%, partial response in 36.8%, and stable disease in 10.5%. The most common toxicities were muscular (57.8%), cutaneous (31.5%), renal (26.3%), hepatic (26.3%), and ophthalmologic (26.3%).Overall, 73.6% of patients required a pharmacist intervention, most frequently for monitoring adverse effects (63.1%), providing additional patient information (31.5%), dose adjustment recommendations (26.3%), drug–drug interaction management (21.1%), medication error prevention (21.1%), and medication reconciliation (10.5%). The acceptance rate of interventions was 89.4%. Following these interventions, 36.8% of patients experienced improved adverse effects, optimised dosing (21%), enhanced patient understanding and adherence and improved coordination of care (26.3%). 31.5% of patients required a dose adjustment of binimetinib, and 21% discontinued treatment, with only one discontinuation due to toxicity.Conclusion and Relevance Pharmaceutical interventions were frequent and essential in patients treated with encorafenib/binimetinib. Their role in monitoring toxicities and supporting treatment adjustments highlights the value of integrating pharmacists into multidisciplinary care teams for melanoma management.Conflict of Interest No conflict of interest